Literature DB >> 14594449

Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors.

Markus-N Kruse1, Christoph Becker, Daniel Lottaz, Danny Köhler, Irene Yiallouros, Hans-Willi Krell, Erwin E Sterchi, Walter Stöcker.   

Abstract

Meprin is a zinc endopeptidase of the astacin family, which is expressed as a membrane-bound or secreted protein in mammalian epithelial cells, in intestinal leucocytes and in certain cancer cells. There are two types of meprin subunits, alpha and beta, which form disulphide-bonded homo- and hetero-oligomers. Here we report on the cleavage of matrix proteins by hmeprin (human meprin) alpha and beta homo-oligomers, and on the interactions of these enzymes with inhibitors. Despite their completely different cleavage specificities, both hmeprin alpha and beta are able to hydrolyse basement membrane components such as collagen IV, nidogen-1 and fibronectin. However, they are inactive against intact collagen I. Hence the matrix-cleaving activity of hmeprin resembles that of gelatinases rather than collagenases. Hmeprin is inhibited by hydroxamic acid derivatives such as batimastat, galardin and Pro-Leu-Gly-hydroxamate, by TAPI-0 (tumour necrosis factor alpha protease inhibitor-0) and TAPI-2, and by thiol-based compounds such as captopril. Therapeutic targets for these inhibitors are MMPs (matrix metalloproteases), TACE (tumour necrosis factor alpha-converting enzyme) and angiotensin-converting enzyme respectively. The most effective inhibitor of hmeprin alpha in the present study was the naturally occurring hydroxamate actinonin ( K(i)=20 nM). The marked variance in the cleavage specificities of hmeprin alpha and beta is reflected by their interaction with the TACE inhibitor Ro 32-7315, whose affinity for the beta subunit (IC50=1.6 mM) is weaker by three orders of magnitude than that for the alpha subunit ( K(i)=1.6 microM). MMP inhibitors such as the pyrimidine-2,4,6-trione derivative Ro 28-2653 that are more specific for gelatinases do not bind to hmeprin, presumably due to the subtle differences in the mode of zinc binding and active-site structure between the astacins and the MMPs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14594449      PMCID: PMC1223953          DOI: 10.1042/BJ20031163

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  47 in total

1.  Heterologously overexpressed, affinity-purified human meprin alpha is functionally active and cleaves components of the basement membrane in vitro.

Authors:  D Köhler; M Kruse; W Stöcker; E E Sterchi
Journal:  FEBS Lett       Date:  2000-01-07       Impact factor: 4.124

2.  Mapping out the basement membrane.

Authors:  R C Liddington
Journal:  Nat Struct Biol       Date:  2001-07

3.  Marked differences between metalloproteases meprin A and B in substrate and peptide bond specificity.

Authors:  G P Bertenshaw; B E Turk; S J Hubbard; G L Matters; J E Bylander; J M Crisman; L C Cantley; J S Bond
Journal:  J Biol Chem       Date:  2001-01-22       Impact factor: 5.157

Review 4.  Fibronectin at a glance.

Authors:  Roumen Pankov; Kenneth M Yamada
Journal:  J Cell Sci       Date:  2002-10-15       Impact factor: 5.285

5.  Proteins of the kidney microvillar membrane. Purification and properties of the phosphoramidon-insensitive endopeptidase ('endopeptidase-2') from rat kidney.

Authors:  A J Kenny; J Ingram
Journal:  Biochem J       Date:  1987-07-15       Impact factor: 3.857

6.  Meprin, a brush-border enzyme, plays an important role in hypoxic/ischemic acute renal tubular injury in rats.

Authors:  Simone Carmago; Sudhir V Shah; Patrick D Walker
Journal:  Kidney Int       Date:  2002-03       Impact factor: 10.612

7.  Acute tubular necrosis due to captopril.

Authors:  S Al Shohaib; E Raweily
Journal:  Am J Nephrol       Date:  2000 Mar-Apr       Impact factor: 3.754

Review 8.  Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.

Authors:  S Zucker; J Cao; W T Chen
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

9.  The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model.

Authors:  Michael Lein; Klaus Jung; Bernhard Ortel; Carsten Stephan; Winfried Rothaug; Rolf Juchem; Manfred Johannsen; Serdar Deger; Dietmar Schnorr; Stefan Loening; Hans-Willi Krell
Journal:  Oncogene       Date:  2002-03-27       Impact factor: 9.867

Review 10.  Strategies for MMP inhibition in cancer: innovations for the post-trial era.

Authors:  Christopher Mark Overall; Carlos López-Otín
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

View more
  65 in total

1.  Balance of meprin A and B in mice affects the progression of experimental inflammatory bowel disease.

Authors:  Sanjita Banerjee; Ge Jin; S Gaylen Bradley; Gail L Matters; Ryan D Gailey; Jacqueline M Crisman; Judith S Bond
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-11-11       Impact factor: 4.052

Review 2.  Pharmacological targets in the renal peritubular microenvironment: implications for therapy for sepsis-induced acute kidney injury.

Authors:  Philip R Mayeux; Lee Ann MacMillan-Crow
Journal:  Pharmacol Ther       Date:  2012-01-16       Impact factor: 12.310

3.  Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease.

Authors:  Sung-Hoon Ahn; Yatrik M Shah; Junko Inoue; Keiichirou Morimura; Insook Kim; Sunhee Yim; Gilles Lambert; Reiko Kurotani; Kunio Nagashima; Frank J Gonzalez; Yusuke Inoue
Journal:  Inflamm Bowel Dis       Date:  2008-07       Impact factor: 5.325

4.  MEP1A allele for meprin A metalloprotease is a susceptibility gene for inflammatory bowel disease.

Authors:  S Banerjee; B Oneda; L M Yap; D P Jewell; G L Matters; L R Fitzpatrick; F Seibold; E E Sterchi; T Ahmad; D Lottaz; J S Bond
Journal:  Mucosal Immunol       Date:  2009-03-04       Impact factor: 7.313

5.  Structural basis for the inhibition of M1 family aminopeptidases by the natural product actinonin: Crystal structure in complex with E. coli aminopeptidase N.

Authors:  Roopa Jones Ganji; Ravikumar Reddi; Rajesh Gumpena; Anil Kumar Marapaka; Tarun Arya; Priyanka Sankoju; Supriya Bhukya; Anthony Addlagatta
Journal:  Protein Sci       Date:  2015-04-08       Impact factor: 6.725

Review 6.  The bone morphogenetic protein 1/Tolloid-like metalloproteinases.

Authors:  Delana R Hopkins; Sunduz Keles; Daniel S Greenspan
Journal:  Matrix Biol       Date:  2007-05-18       Impact factor: 11.583

7.  The metalloprotease meprin β generates amino terminal-truncated amyloid β peptide species.

Authors:  Jessica Bien; Tamara Jefferson; Mirsada Causević; Thorsten Jumpertz; Lisa Munter; Gerd Multhaup; Sascha Weggen; Christoph Becker-Pauly; Claus U Pietrzik
Journal:  J Biol Chem       Date:  2012-08-09       Impact factor: 5.157

Review 8.  Meprin A metalloproteinase and its role in acute kidney injury.

Authors:  Gur P Kaushal; Randy S Haun; Christian Herzog; Sudhir V Shah
Journal:  Am J Physiol Renal Physiol       Date:  2013-02-20

Review 9.  Meprins, membrane-bound and secreted astacin metalloproteinases.

Authors:  Erwin E Sterchi; Walter Stöcker; Judith S Bond
Journal:  Mol Aspects Med       Date:  2008-08-22

10.  Prointerleukin-18 is activated by meprin beta in vitro and in vivo in intestinal inflammation.

Authors:  Sanjita Banerjee; Judith S Bond
Journal:  J Biol Chem       Date:  2008-09-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.